

SFY 2021 - 2022 MC MLR Summary  
HIV SNP line of business

| Plan                                    | MLR AFTER<br>Credibility<br>Adjustment | Medical<br>Expense<br>(Total<br>Numerator) | Premium<br>(Total<br>Denominator) | Remittance | Credible           | MMs     |
|-----------------------------------------|----------------------------------------|--------------------------------------------|-----------------------------------|------------|--------------------|---------|
| Amida Care Inc.                         | 89.61%                                 | \$435,922,516                              | \$497,472,426                     | \$0        | Partially Credible | 100,680 |
| MetroPlus Health Plan, Inc.             | 96.42%                                 | \$237,380,758                              | \$253,437,986                     | \$0        | Partially Credible | 55,644  |
| VNS (d/b/a VNSNY Choice) and Subsidiary | 95.83%                                 | \$184,180,623                              | \$199,407,628                     | \$0        | Partially Credible | 35,527  |
| Total                                   |                                        | \$857,483,897                              | \$950,318,040                     | \$0        |                    | 191,851 |

NOTES:

Please note that the Remittance is for this line of business for one year ONLY based on a MLR Target of 86%.

No remittance for plan if **Non-Credible**